Overview
Provectus Algae develops scalable biomanufacturing platforms using photosynthetic microalgae and Precision Photosynthesis technology to produce high-value compounds for pharmaceuticals, nutraceuticals, and therapeutics. Their closed-system bioreactors enable controlled production of target substances like peptides, proteins, and bioactive ingredients for drug development and synthetic biology applications. The company supports R&D in sustainable bioproducts across food, cosmetics, agriculture, and pharma sectors.
Frequently asked questions
- What biomanufacturing capabilities does Provectus Algae offer for pharma R&D?
- Provectus Algae provides modular, automated bioreactors with Precision Photosynthesis and AI-enabled systems to produce high-value microalgae compounds, including peptides and proteins via chloroplast expression for therapeutics and synthetic biology.
- What industries and applications do they serve?
- They target pharmaceuticals, nutraceuticals, cosmetics, food & beverage, agriculture, and therapeutics with sustainable algae-derived ingredients like bioactive compounds, UV-blockers, antioxidants, and feed supplements.
- What is their production scale and geographic focus?
- Operating from Australia with capacities scaling from 110,000 to 260,000 liters, their modular systems can deploy globally; they plan US expansion and emphasize contamination-controlled, closed-loop production.